(Reuters) – The U.S. health regulator is delaying a decision on authorizing Moderna Inc’s COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of heart inflammation, the Wall Street Journal reported on Friday, citing people familiar with the matter.
(Reporting by Amruta Khandekar; Editing by Devika Syamnath)
